By Pete Lawyer, Marin Gjaja and Rob Alford
This article is the second in a two-part series from The Boston Consulting Group (BCG) exploring the financial rationale driving...
Feeding the Beast: Steady M&A Diet Fuels VAlue for Big Device Firms
Natural selection by the markets will ensure the largest device companies will win out over industrial newcomers in buying smaller players, maximizing value creation and growing larger and stronger.
More from Archive
More from In Vivo
• By
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
• By
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.